Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 7;13:12501–12513. doi: 10.2147/OTT.S280142

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Zhong et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

H19 targets miR-130a-3p. (A) Predicted binding sites of miR-130a-3p in H19 3ʹ-UTR. (B and C) Dual-luciferase reporter gene detection and RNA immunoprecipitation assay confirmed the relationship between H19 and miR-130a-3p. (D) MiR-130a-3p was downregulated in BC tissues compared to adjacent normal tissues. (E) MiR-130a-3p level was significantly decreased in BC cells compared to MCF-10A cells. (F and G) The miR-130a-3p mimic increased miR-130a-3p expression compared to negative controls (NC), while miR-130a-3p inhibitor decreased the expression of miR-130a-3p. (H) Negative correlation between H19 and miR-130a-3p expression in breast cancer tissues. **P < 0.01, compared to the NC group; ^##P < 0.01, compared to the inhibitor group.